Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy
Frontiers in Pharmacology · 01.07.2026 · 17
DOI: 10.3389/fphar.2026.1868002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 01.07.2026. Verfasst von Damiana Scuteri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University "Magna Grӕcia"of Catanzaro, Catanzaro, Italy. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Migraine is a disabling neurovascular disorder that may evolve from episodic to chronic forms, often complicated by medication-overuse headache (MOH). It generates substantial healthcare expenditures and indirect societal costs. Pharmacological constraints and resistance to acute therapies contribute to the development of MOH and increase the need for preventive treatments such as onabotulinumtoxin A (BoNT/A) and monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
Objective
This pharmacoepidemiology retrospective study aimed to evaluate real-world prescription patterns of BoNT/A and anti-CGRP/R mAbs in an Italian regional setting and to compare current data (2023–2024) with previously observed patterns (2020–2022) before the integration of pharmacists as outpost in migraine man-agement.
Methods
Anonymized data were obtained from the regional drug reimbursement and prescription database.
Results
A total of 9,012 and 9,705 prescriptions were recorded in 2023 and 2024, respectively, indicating an increasing trend in the use of innovative preventive therapies. A gradual increase in the use of eptinezumab and BoNT/A appears to be associated with regional organizational measures aimed at improving access to care, adherence to clinical guidelines, and integrated management across healthcare levels.
Conclusion
Therapeutic appropriateness is far from reaching the gold standard and an increasing role of pharmacists could improve clinical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Sciences, University "Magna Grӕcia"of Catanzaro, Catanzaro, Italy.
- Directorate-General for Animal Health, Ministry of Health, Rome, Italy.
- Department of Pharmacy, Preclinical and Translational Pharmacology, Health and Nutritional Sciences, University of Calabria, Rende, Cosenza, Italy.
- Pharmacy Unit, AOU Renato Dulbecco, Catanzaro, Italy.
- Department of Biotechnology, Dublin City University, Dublin, Ireland.
Zitieren
APA
Scuteri, D., Naturale, M. D., Pagliaro, M., Brescia, A., De Francesco, A. E., Lawrence, G. W., Bagetta, G., & Corasaniti, M. T. (2026). Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1868002
Vancouver
Scuteri D, Naturale MD, Pagliaro M, Brescia A, De Francesco AE, Lawrence GW, et al. Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1868002
BibTeX
@article{Scuteri2026,
author = {Scuteri, Damiana and Naturale, Maria Diana and Pagliaro, Martina and Brescia, Amelia and De Francesco, Adele Emanuela and Lawrence, Gary W and Bagetta, Giacinto and Corasaniti, Maria Tiziana},
title = {Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1868002}
}
EUVIMED